The Case Volume Issue in Head and Neck Oncology
- 226 Downloads
In the past few years, several evidences reported better outcomes, in terms of reduced toxicities and longer survival, for head and neck cancer (HNC) patients when “regionalized,” namely if they are managed at “high-volume” cancer referral centers (CRC). The benefit of case volume has been demonstrated in HNC patients primarily treated with surgery and in those receiving curative radiotherapy and chemotherapy. Many factors could explain these positive results: organization, facilities, processes of care, quality assurance programs, professional expertise, technology, and patient referral bias. In other words, the “high volume” could be linked both to all hospital-related volume and to the expertise of each involved professional figure (e.g., surgeon, radiation oncologist, medical oncologist, etc.). In this context, it is still debatable whether there is a need to understand which one of these factors is more able to influence the final outcomes of HNC patients. Considering the complexity and heterogeneity of HNC, all of these aspects are likely to impact and plot each other. However, there is no consensus regarding the criteria and the cut-off used to define as “high” the case volume. Moreover, some limitations or biases of the regionalization process have to be highlighted: (1) personal and financial discomfort of patients, their caregivers, and families; (2) a frequent referral of the healthiest or youngest patients to CRC could change the survival outcomes; (3) potential higher difficulties for colleagues working outside of CRC in the emergency. Nevertheless, the case volume represents one of the factors impacting on the quality of the treatment itself, in terms of reduced toxicity and better treatment outcome. Therefore, it should be considered as a stratifying factor in randomized controlled trials for HNC patients.
KeywordsHead and neck cancer Case volume Surgery Chemotherapy Radiation
Compliance with Ethical Standards
Conflict of Interest
Salvatore Alfieri declares that he has no conflict of interest.
Ester Orlandi declares that she has no conflict of interest.
Paolo Bossi has received research support through grants from Merck Serono and Molteni and has received compensation from Merck Serono, AstraZeneca, Kyowa Kirin, Roche, Molteni, and Mundipharma for service as a consultant.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.• Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349(22):2117–27. This study assessed the hospital-related case volume, after adjusting for a surgeon case volume, as the strongest predictor of decreased mortality in few surgical procedures (lung and pancreatic resection, repair of an abdominal aortic aneurysm, and cystectomy). The need of a peri-operative long stay and the importance of all hospital-based services could reasonably explain such an influence from the hospital rather than the surgeon volume.CrossRefPubMedGoogle Scholar
- 3.Urbach DR, Bell CM, Austin PC. Differences in operative mortality between high- and low-volume hospitals in Ontario for 5 major surgical procedures: estimating the number of lives potentially saved through regionalization. Can Med Assoc J. 2003;168(11):1409–14.Google Scholar
- 6.•• Eskander A, Merdad M, Irish JC, Hall SF, Groome PA, Freeman JL, et al. Volume-outcome associations in head and neck cancer treatment: a systematic review and meta-analysis. Head Neck. 2014;36(12):1820–34. This is a review and meta-analysis of all the studies investigating the relationship between the case volume (hospital and/or surgeon-related) and survival outcomes in the context of multimodality treatment of head and neck cancer patients.CrossRefPubMedGoogle Scholar
- 13.•• Eskander A, Irish J, Groome PA, Freeman J, Gullane P, Gilbert R, et al. Volume-outcome relationships for head and neck cancer surgery in a universal health care system. Laryngoscope. 2014;124(9):2081–8. This was the first study confirming in head and neck cancer surgery the hospital volume as the significant and most robust predictor of better survival at multivariate analysis.CrossRefPubMedGoogle Scholar
- 17.• Peters LJ, O’Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol. 2010;28:2996–3001. Secondary analysis of the Trans-Tasman Radiation Oncology Group trial showing how non-compliant radiation plans were observed more frequently in low accruing sites; non-compliance was associated with reduced survival.CrossRefPubMedGoogle Scholar
- 18.World Health Organization (WHO). Quality Assurance in Radiotherapy. Geneva: WHO; 1998.Google Scholar
- 19.Rischin D, Peters L, O’Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010;28:2989–95.CrossRefPubMedGoogle Scholar
- 21.• Boero I, Paravati A, Xu B, Cohen EE, Mell LK, Le QT, et al. Importance of radiation oncologist experience among patients with head-and-neck cancer treated with intensity-modulated radiation therapy. J Clin Oncol. 2016;34(7):684–90. Analysis conducted on data from US individual cancer registries. Patients receiving IMRT and treated by high-volume providers showed a decrease in all-cause mortality and less toxicities, namely less aspiration pneumonia.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.•• Wuthrick EJ, Zhang Q, Machtay M, et al. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015;33:156–64. Analysis of the single-center experience within the RTOG 0129 trial comparing accelerated RT with RT concurrent to cisplatin. As surrogate of expertise, the number of patients enrolled in previous RTOG trials was considered. High historical accruing centers showed the greater benefit in terms of overall survival.CrossRefPubMedGoogle Scholar
- 30.Bergamini C, Locati L, Bossi P, Granata R, Alfieri S, Resteghini C, et al. Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? Oral Oncol. 2016;54:54–7. https://doi.org/10.1016/j.oraloncology.2016.01.001.CrossRefPubMedGoogle Scholar
- 31.Beswick DM, Vashi A, Song Y, Pham R, Holsinger FC, Rayl JD, et al. Consultation via telemedicine and access to operative care for patients with head and neck cancer in a veterans health administration population. Head Neck. 2016;38(6):925–9. https://doi.org/10.1002/hed.24386.CrossRefPubMedGoogle Scholar